Managing Complexity: Care Coordination for CNS Metastases
Panelists discuss the current standard of care for metastatic melanoma with asymptomatic brain metastases, emphasizing the durability of CTLA-4 plus PD-1 immunotherapy, the emerging but unproven role of newer combinations like PD-1 plus LAG-3, and the importance of multidisciplinary coordination, patient education, and timely intervention in managing both asymptomatic and symptomatic brain involvement.
For patients with metastatic melanoma and asymptomatic brain metastases, immunotherapy remains the standard of care, particularly the combination of CTLA-4 and PD-1 inhibitors. While newer combinations like PD-1 and LAG-3 inhibitors show potential, their intracranial efficacy is still under investigation. For now, CTLA-4 and PD-1 blockade offers the most durable response and is preferred for patients who are not on steroids. In research settings, patients may be considered for trials exploring newer combinations, but clinical decision-making should still prioritize treatments with the strongest evidence for brain activity.
In cases involving symptomatic brain metastases, treatment becomes more complex. For patients requiring steroids or experiencing significant neurologic symptoms, targeted therapies may be used temporarily to reduce tumor burden and improve clinical stability. These therapies offer quick but short-lived responses and can serve as a bridge to immunotherapy once the patient is stable. Close collaboration with neurosurgery and radiation oncology is essential, especially when surgery or radiation is required to control symptoms or lower steroid use before initiating immunotherapy.
Effective management also involves comprehensive patient education and multidisciplinary coordination. Patients often face overwhelming information, so establishing clear communication and frequent follow-up, such as brain MRIs every 6 weeks, is key. Care teams should educate both patients and their families on subtle neurological symptoms, reinforce the importance of reporting changes from baseline, and remain vigilant about distinguishing treatment-related toxicities from disease progression. Continuous communication with radiation oncologists and neurosurgeons ensures timely interventions, while consistent neurological assessments help guide safe and effective care. This holistic approach has significantly improved outcomes for a patient population that once had limited options.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
